Does Geisinger Health Plan Cover Forteo (Teriparatide)?

How Geisinger Health Plan Classifies Forteo on Its Formulary

Geisinger Health Plan places Forteo (teriparatide 20 mcg/dose injection pen) on its specialty pharmacy tier across most commercial and Medicare Advantage formularies. Specialty-tier drugs carry higher cost-sharing than standard generic or preferred-brand medications, and they require dispensing through Geisinger's preferred specialty pharmacy network.

Commercial vs. Medicare Advantage Placement

On Geisinger's commercial plans, Forteo sits on Tier 4 or Tier 5 (specialty). Members on commercial HMO or PPO products can expect coinsurance of 20% to 33% of the drug's cost after deductible. For Medicare Advantage members enrolled in Geisinger Gold, Forteo falls under Part D specialty tier coverage. The 2025 Medicare Part D redesign capped annual out-of-pocket drug spending at $2,000, which benefits patients on high-cost specialty medications like teriparatide [1]. Before the cap took effect, annual Forteo costs could exceed $6,000 out of pocket for Medicare beneficiaries.

Specialty Pharmacy Requirements

Geisinger mandates that Forteo be filled through its specialty pharmacy partner. Retail pharmacy fills are not covered. The specialty pharmacy coordinates delivery, provides injection training, and manages refill scheduling. Members who attempt to fill at a non-preferred specialty pharmacy may face full out-of-pocket cost or a coverage denial.

Prior Authorization Criteria for Forteo

Geisinger Health Plan requires prior authorization (PA) for Forteo across all plan types. The PA process confirms medical necessity and verifies that the patient meets clinical criteria before the plan approves coverage.

Clinical Documentation Needed

To approve Forteo, Geisinger's pharmacy benefit management team generally requires the following documentation from the prescribing provider:

• A dual-energy X-ray absorptiometry (DXA) scan showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip
• OR documentation of a low-trauma (fragility) fracture at the hip or spine
• Evidence of trial and failure of, intolerance to, or contraindication to at least one oral bisphosphonate (alendronate or risedronate) for a minimum of 12 months
• Confirmation that the patient does not have contraindications to teriparatide, including unexplained elevated alkaline phosphatase, Paget's disease, prior radiation therapy to the skeleton, open epiphyses, or pre-existing hypercalcemia

These requirements align with the American Association of Clinical Endocrinology (AACE) 2020 guidelines, which recommend anabolic agents like teriparatide for patients at very high fracture risk, particularly those with vertebral fractures or T-scores below -2.5 with additional risk factors [2].

Turnaround Time

Standard PA review takes 5 to 10 business days. Urgent (expedited) reviews can be completed within 72 hours when the prescriber documents clinical urgency. If the PA is denied, Geisinger issues a written explanation with instructions for appeal.

What Forteo Costs Under Geisinger Plans

The retail price of Forteo without insurance averages approximately $4,200 for a 28-day supply (one 2.4 mL pen delivering 20 mcg daily). With Geisinger coverage, actual patient costs depend on plan design, tier placement, and whether the member has met their annual deductible.

Estimated Out-of-Pocket Costs

For Geisinger commercial plans with specialty coinsurance of 25%, a member would owe roughly $1,050 per month before any manufacturer assistance. Plans with a flat specialty copay may charge $150 to $500 per fill. Geisinger Gold Medicare Advantage members benefit from the $2,000 annual Part D out-of-pocket cap. Once that threshold is reached, the member pays $0 for the remainder of the calendar year [1].

Reducing Your Costs

Eli Lilly offers the Forteo Savings Card for commercially insured patients, which can reduce copays to as low as $4 per month for eligible members. This card does not apply to government insurance (Medicare, Medicaid, Tricare). Medicare patients may qualify for Lilly's Patient Assistance Program (LillyPAP), which provides Forteo at no cost to patients who meet income requirements (generally below 400% of the federal poverty level).

The biosimilar teriparatide product (marketed as Teriparatide-Teva) received FDA approval and may appear on Geisinger formularies at a lower tier or with reduced cost-sharing compared to brand Forteo. Patients should ask their provider or Geisinger's member services whether the biosimilar is available and preferred.

Clinical Evidence Supporting Forteo for Osteoporosis

Teriparatide is the first FDA-approved anabolic (bone-building) agent for osteoporosis. Unlike bisphosphonates, which slow bone breakdown, teriparatide stimulates new bone formation by activating osteoblasts.

The Fracture Prevention Trial

The key Fracture Prevention Trial (FPT, N=1,637) randomized postmenopausal women with prior vertebral fractures to teriparatide 20 mcg/day, teriparatide 40 mcg/day, or placebo. At a median follow-up of 21 months, the 20 mcg dose reduced new vertebral fractures by 65% (relative risk 0.35, 95% CI 0.22 to 0.55) and nonvertebral fragility fractures by 53% (relative risk 0.47, 95% CI 0.25 to 0.88) compared with placebo [3]. Lumbar spine bone mineral density (BMD) increased by 9.7% and femoral neck BMD by 2.8%.

VERO Trial: Teriparatide vs. Risedronate

The VERO trial (N=1,360) directly compared teriparatide to risedronate in postmenopausal women with at least two moderate or one severe vertebral fracture. After 24 months, teriparatide reduced new vertebral fractures by 56% compared with risedronate (HR 0.44, 95% CI 0.29 to 0.68, P<0.001) and clinical fractures by 52% (HR 0.48, 95% CI 0.32 to 0.74, P<0.001) [4]. This trial was significant because it showed superiority of an anabolic agent over an active antiresorptive comparator, not just placebo.

Sequential Therapy Considerations

Current evidence strongly supports following teriparatide with an antiresorptive agent (bisphosphonate or denosumab) to maintain BMD gains. The DATA-Switch study demonstrated that women who received teriparatide for 2 years followed by denosumab for 2 years achieved total hip BMD increases of 12.9%, the largest gains reported in any osteoporosis trial [5]. Stopping teriparatide without transition to an antiresorptive leads to rapid bone loss within 12 months.

How to Get Forteo Approved Through Geisinger

Navigating the approval process requires coordination between you, your provider, and Geisinger's pharmacy team. A structured approach minimizes delays.

Step 1: Confirm Your Formulary

Call the member services number on the back of your Geisinger ID card or log into geisinger.org to check your plan's formulary. Verify whether brand Forteo, biosimilar teriparatide, or both are listed, and note the tier and any PA or step-therapy requirements.

Step 2: Gather Documentation

Your provider needs to submit the PA with your most recent DXA scan, fracture history, and documentation of prior bisphosphonate therapy. If you have a contraindication to bisphosphonates (such as esophageal stricture, inability to remain upright for 30 minutes, or documented GI intolerance), your provider should state this explicitly.

Step 3: Submit and Track the PA

Your provider's office submits the PA electronically or by fax to Geisinger. Ask for the reference number and follow up if you haven't received a decision within 10 business days. If approval comes through, the specialty pharmacy will contact you to arrange delivery and provide injection training.

Step 4: Appeal a Denial

If Geisinger denies coverage, you have the right to appeal. The denial letter specifies the reason (often insufficient documentation of bisphosphonate failure or missing DXA results). Your provider can submit additional records. Geisinger allows internal appeals within 180 days of the denial. If the internal appeal is denied, you can request an external review by an independent organization. The Endocrine Society's 2020 clinical practice guideline recommends teriparatide as first-line therapy for patients at very high fracture risk, and citing this guideline in an appeal letter strengthens the clinical argument [6].

Forteo Safety Profile and Monitoring on Geisinger Plans

Geisinger's specialty pharmacy program includes monitoring touchpoints during the Forteo treatment course. This oversight helps identify adverse effects early and supports adherence.

Common Side Effects

The most frequently reported side effects in clinical trials include injection-site reactions (pain, redness, swelling), dizziness, leg cramps, nausea, and joint pain. Orthostatic hypotension can occur within 4 hours of injection, particularly during the first several doses. The FPT reported transient hypercalcemia (serum calcium above 10.6 mg/dL) in 11% of teriparatide-treated patients versus 2% of placebo patients [3].

The Black Box Warning

Forteo carries an FDA black box warning based on a preclinical finding: Fischer 344 rats given teriparatide at doses 3 to 58 times the human dose developed osteosarcoma (bone cancer) at high rates. No causal link has been established in humans. A 15-year postmarketing surveillance study by Eli Lilly found no increase in osteosarcoma incidence among teriparatide-treated patients compared with the general population [7]. The FDA extended the maximum approved treatment duration from 18 to 24 months in 2009, and the Endocrine Society has noted that the osteosarcoma signal has not been replicated in primates or humans [6].

Monitoring Schedule

Geisinger's specialty pharmacy typically calls patients at 2 weeks, 1 month, and every 3 months thereafter to assess injection technique, adherence, and side effects. Serum calcium should be checked at 1 month and then as clinically indicated. A follow-up DXA scan is generally performed at 12 to 24 months to assess treatment response. The AACE recommends checking 24-hour urine calcium if patients develop symptoms of hypercalcemia [2].

Alternatives If Geisinger Denies Forteo Coverage

If Forteo is denied and appeals are exhausted, several alternatives exist for patients who need osteoporosis treatment beyond oral bisphosphonates.

Denosumab (Prolia)

Denosumab is a RANK ligand inhibitor administered as a subcutaneous injection every 6 months. Geisinger Health Plan covers denosumab under its medical benefit (not pharmacy benefit) in most plan designs. The FREEDOM trial (N=7,868) showed denosumab reduced vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 3 years compared with placebo [8]. Denosumab does not require the same step-therapy documentation as teriparatide on most formularies because it is classified as an antiresorptive rather than an anabolic agent.

Romosozumab (Evenity)

Romosozumab is a sclerostin inhibitor with both anabolic and antiresorptive properties, approved for postmenopausal women at high fracture risk. The ARCH trial (N=4,093) showed romosozumab for 12 months followed by alendronate reduced vertebral fracture risk by 48% compared with alendronate alone over a median of 33 months [9]. Geisinger may cover romosozumab under specialty tier with PA, though cardiovascular risk screening is required due to a signal for increased major adverse cardiac events observed in the ARCH trial.

Abaloparatide (Tymlos)

Abaloparatide is a parathyroid hormone-related peptide analog. The ACTIVE trial (N=2,463) demonstrated that abaloparatide reduced new vertebral fractures by 86% and nonvertebral fractures by 43% compared with placebo over 18 months [10]. It carries a similar black box warning as teriparatide regarding osteosarcoma risk in rats. Formulary placement on Geisinger plans varies, but it may be considered as an alternative anabolic agent if teriparatide is denied.

Geisinger-Specific Resources and Contact Information

Geisinger Health Plan operates primarily in Pennsylvania, serving members across commercial, Medicare Advantage (Geisinger Gold), and Medicaid (Geisinger Family) products. For coverage questions specific to Forteo:

• Member Services (Commercial): Call the number on your ID card or visit geisinger.org
• Geisinger Gold (Medicare Advantage): 800-447-4000
• Pharmacy Benefits: Geisinger uses internal pharmacy benefit management for most plans; specialty drugs route through their preferred specialty pharmacy
• Prior Authorization Fax: Your provider can find the PA fax number on Geisinger's provider portal

Patients enrolled in Geisinger Medicaid plans should check with their plan coordinator, as Medicaid formularies may have different step-therapy and PA requirements than commercial or Medicare products.